Literature DB >> 32857985

Physical and Functional Analysis of the Putative Rpn13 Inhibitor RA190.

Paige Dickson1, Daniel Abegg1, Ekaterina Vinogradova2, Junichiro Takaya2, Hongchan An1, Scott Simanski1, Benjamin F Cravatt2, Alexander Adibekian1, Thomas Kodadek3.   

Abstract

Rpn13 is one of several ubiquitin receptors in the 26S proteasome. Cys88 of Rpn13 has been proposed to be the principal target of RA190, an electrophilic small molecule with interesting anti-cancer activities. Here, we examine the claim that RA190 mediates its cytotoxic effects through engagement with Rpn13. We find no evidence that this is the case. In vitro, RA190 is has no measurable effect on any of the known interactions of Rpn13. In cellulo, we see no physical engagement of Rpn13 by RA190, either on C88 or any other residue. However, chemical proteomics experiments in two different cell lines reveal that dozens of other proteins are heavily engaged by RA190. Finally, increasing or reducing the level of Rpn13 in HeLa and melanoma cells had no effect on the sensitivity of HeLa or melanoma cells to RA190. We conclude that Rpn13 is not the physiologically relevant target of RA190.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Rpn13:RA190; cancer chemotherapy; proteasome; ubiquitin

Mesh:

Substances:

Year:  2020        PMID: 32857985      PMCID: PMC7680414          DOI: 10.1016/j.chembiol.2020.08.007

Source DB:  PubMed          Journal:  Cell Chem Biol        ISSN: 2451-9448            Impact factor:   8.116


  41 in total

1.  Structure and energetics of pairwise interactions between proteasome subunits RPN2, RPN13, and ubiquitin clarify a substrate recruitment mechanism.

Authors:  Ryan T VanderLinden; Casey W Hemmis; Tingting Yao; Howard Robinson; Christopher P Hill
Journal:  J Biol Chem       Date:  2017-04-25       Impact factor: 5.157

2.  Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells.

Authors:  N E Franke; D Niewerth; Y G Assaraf; J van Meerloo; K Vojtekova; C H van Zantwijk; S Zweegman; E T Chan; C J Kirk; D P Geerke; A D Schimmer; G J L Kaspers; G Jansen; J Cloos
Journal:  Leukemia       Date:  2011-09-23       Impact factor: 11.528

3.  Capzimin is a potent and specific inhibitor of proteasome isopeptidase Rpn11.

Authors:  Jing Li; Tanya Yakushi; Francesco Parlati; Andrew L Mackinnon; Christian Perez; Yuyong Ma; Kyle P Carter; Sharon Colayco; Gavin Magnuson; Brock Brown; Kevin Nguyen; Stefan Vasile; Eigo Suyama; Layton H Smith; Eduard Sergienko; Anthony B Pinkerton; Thomas D Y Chung; Amy E Palmer; Ian Pass; Sonja Hess; Seth M Cohen; Raymond J Deshaies
Journal:  Nat Chem Biol       Date:  2017-02-28       Impact factor: 15.040

4.  Targeting Stereotyped B Cell Receptors from Chronic Lymphocytic Leukemia Patients with Synthetic Antigen Surrogates.

Authors:  Mohosin Sarkar; Yun Liu; Junpeng Qi; Haiyong Peng; Jumpei Morimoto; Christoph Rader; Nicholas Chiorazzi; Thomas Kodadek
Journal:  J Biol Chem       Date:  2016-02-05       Impact factor: 5.157

5.  Proteasome recruitment and activation of the Uch37 deubiquitinating enzyme by Adrm1.

Authors:  Tingting Yao; Ling Song; Wei Xu; George N DeMartino; Laurence Florens; Selene K Swanson; Michael P Washburn; Ronald C Conaway; Joan Weliky Conaway; Robert E Cohen
Journal:  Nat Cell Biol       Date:  2006-08-13       Impact factor: 28.824

6.  Knockdown of ovarian cancer amplification target ADRM1 leads to downregulation of GIPC1 and upregulation of RECK.

Authors:  Marlena S Fejzo; Chuck Ginther; Judy Dering; Lee Anderson; Natarajan Venkatesan; Gottfried Konecny; Beth Karlan; Dennis J Slamon
Journal:  Genes Chromosomes Cancer       Date:  2011-03-22       Impact factor: 5.006

7.  Knockdown of the novel proteasome subunit Adrm1 located on the 20q13 amplicon inhibits colorectal cancer cell migration, survival and tumorigenicity.

Authors:  Wei Chen; Xiao-Tong Hu; Qing-Lan Shi; Fu-Biao Zhang; Chao He
Journal:  Oncol Rep       Date:  2009-02       Impact factor: 3.906

Review 8.  The growing impact of click chemistry on drug discovery.

Authors:  Hartmuth C Kolb; K Barry Sharpless
Journal:  Drug Discov Today       Date:  2003-12-15       Impact factor: 7.851

Review 9.  Efficacy of therapy with bortezomib in solid tumors: a review based on 32 clinical trials.

Authors:  Zebo Huang; Yinxia Wu; Xin Zhou; Jun Xu; Wei Zhu; Yongqian Shu; Ping Liu
Journal:  Future Oncol       Date:  2014-08       Impact factor: 3.404

10.  A High Affinity hRpn2-Derived Peptide That Displaces Human Rpn13 from Proteasome in 293T Cells.

Authors:  Xiuxiu Lu; Fen Liu; Sarah E Durham; Sergey G Tarasov; Kylie J Walters
Journal:  PLoS One       Date:  2015-10-14       Impact factor: 3.240

View more
  5 in total

1.  26S proteasomes become stably activated upon heat shock when ubiquitination and protein degradation increase.

Authors:  Donghoon Lee; Alfred L Goldberg
Journal:  Proc Natl Acad Sci U S A       Date:  2022-06-15       Impact factor: 12.779

Review 2.  Proteasome interaction with ubiquitinated substrates: from mechanisms to therapies.

Authors:  Xiang Chen; Zaw Min Htet; Erika López-Alfonzo; Andreas Martin; Kylie J Walters
Journal:  FEBS J       Date:  2020-12-11       Impact factor: 5.622

3.  Structure-guided bifunctional molecules hit a DEUBAD-lacking hRpn13 species upregulated in multiple myeloma.

Authors:  Xiuxiu Lu; Venkata R Sabbasani; Vasty Osei-Amponsa; Christine N Evans; Julianna C King; Sergey G Tarasov; Marzena Dyba; Sudipto Das; King C Chan; Charles D Schwieters; Sulbha Choudhari; Caroline Fromont; Yongmei Zhao; Bao Tran; Xiang Chen; Hiroshi Matsuo; Thorkell Andresson; Raj Chari; Rolf E Swenson; Nadya I Tarasova; Kylie J Walters
Journal:  Nat Commun       Date:  2021-12-16       Impact factor: 14.919

4.  Comprehensive Target Screening and Cellular Profiling of the Cancer-Active Compound b-AP15 Indicate Abrogation of Protein Homeostasis and Organelle Dysfunction as the Primary Mechanism of Action.

Authors:  Johannes Gubat; Karthik Selvaraju; Linda Sjöstrand; Dhananjay Kumar Singh; Maria V Turkina; Bernhard Schmierer; Pierre Sabatier; Roman A Zubarev; Stig Linder; Pádraig D'Arcy
Journal:  Front Oncol       Date:  2022-04-22       Impact factor: 5.738

5.  Chirality and asymmetry increase the potency of candidate ADRM1/RPN13 inhibitors.

Authors:  Ravi K Anchoori; Logan George; Ssu-Hsueh Tseng; Brandon Lam; Srinidhi Polkampally; Anjali D Amiano; Palmer Foran; Hannah Tsingine; Harideep Samanapally; Fernanda Carrizo Velasquez; Samarjit Das; Deyin Xing; Ahmad Bin Salam; Balasubramanyam Karanam; Chien-Fu Hung; Richard B S Roden
Journal:  PLoS One       Date:  2021-09-10       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.